ID   MECR_HUMAN              Reviewed;         373 AA.
AC   Q9BV79; B3KT72; Q5SYU0; Q5SYU1; Q5SYU2; Q6IBU9; Q9Y373;
DT   26-APR-2005, integrated into UniProtKB/Swiss-Prot.
DT   31-MAY-2011, sequence version 2.
DT   10-MAY-2017, entry version 142.
DE   RecName: Full=Enoyl-[acyl-carrier-protein] reductase, mitochondrial {ECO:0000305};
DE            EC=1.3.1.104 {ECO:0000305|PubMed:12654921, ECO:0000305|PubMed:18479707};
DE   AltName: Full=2-enoyl thioester reductase;
DE   AltName: Full=Nuclear receptor-binding factor 1;
DE            Short=HsNrbf-1;
DE            Short=NRBF-1;
DE   Flags: Precursor;
GN   Name=MECR; Synonyms=NBRF1; ORFNames=CGI-63;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   LEU-96.
RX   PubMed=10810093; DOI=10.1101/gr.10.5.703;
RA   Lai C.-H., Chou C.-Y., Ch'ang L.-Y., Liu C.-S., Lin W.-C.;
RT   "Identification of novel human genes evolutionarily conserved in
RT   Caenorhabditis elegans by comparative proteomics.";
RL   Genome Res. 10:703-713(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT
RP   LEU-96.
RC   TISSUE=Hippocampus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   LEU-96.
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT LEU-96.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   LEU-96.
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   ENZYME ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, SUBUNIT, SUBCELLULAR
RP   LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=12654921; DOI=10.1074/jbc.M302851200;
RA   Miinalainen I.J., Chen Z.-J., Torkko J.M., Pirilae P.L.,
RA   Sormunen R.T., Bergmann U., Qin Y.-M., Hiltunen J.K.;
RT   "Characterization of 2-enoyl thioester reductase from mammals: an
RT   ortholog of Ybr026p/Mrf1'p of the yeast mitochondrial fatty acid
RT   synthesis type II.";
RL   J. Biol. Chem. 278:20154-20161(2003).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [9]
RP   SUBCELLULAR LOCATION (ISOFORM 2).
RX   PubMed=25031892; DOI=10.3803/EnM.2014.29.2.185;
RA   Kim D.G., Yoo J.C., Kim E., Lee Y.S., Yarishkin O.V., Lee da Y.,
RA   Lee K.H., Hong S.G., Hwang E.M., Park J.Y.;
RT   "A novel cytosolic isoform of mitochondrial Trans-2-Enoyl-CoA
RT   reductase enhances peroxisome proliferator-activated receptor alpha
RT   activity.";
RL   Endocrinol. Metab. 29:185-194(2014).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 40-373.
RG   Structural genomics consortium (SGC);
RT   "The structure of human mitochondrial 2-enoyl thioester reductase
RT   (CGI-63).";
RL   Submitted (JUN-2005) to the PDB data bank.
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (2.41 ANGSTROMS) OF 31-373, FUNCTION, CATALYTIC
RP   ACTIVITY, SUBUNIT, BIOPHYSICOCHEMICAL PROPERTIES, AND MUTAGENESIS OF
RP   SER-85; TYR-94; ILE-129; GLY-165; THR-170; TRP-311 AND PHE-324.
RX   PubMed=18479707; DOI=10.1016/j.jmb.2008.04.041;
RA   Chen Z.J., Pudas R., Sharma S., Smart O.S., Juffer A.H.,
RA   Hiltunen J.K., Wierenga R.K., Haapalainen A.M.;
RT   "Structural enzymological studies of 2-enoyl thioester reductase of
RT   the human mitochondrial FAS II pathway: new insights into its
RT   substrate recognition properties.";
RL   J. Mol. Biol. 379:830-844(2008).
RN   [14]
RP   INVOLVEMENT IN DYTOABG, VARIANTS DYTOABG GLU-232; TRP-258;
RP   285-TYR--MET-373 DEL AND CYS-285, CHARACTERIZATION OF VARIANTS DYTOABG
RP   GLU-232 AND 285-TYR--MET-373 DEL, AND FUNCTION.
RX   PubMed=27817865; DOI=10.1016/j.ajhg.2016.09.021;
RG   University of Washington Center for Mendelian Genomics;
RA   Heimer G., Keraetaer J.M., Riley L.G., Balasubramaniam S., Eyal E.,
RA   Pietikaeinen L.P., Hiltunen J.K., Marek-Yagel D., Hamada J.,
RA   Gregory A., Rogers C., Hogarth P., Nance M.A., Shalva N., Veber A.,
RA   Tzadok M., Nissenkorn A., Tonduti D., Renaldo F., Kraoua I.,
RA   Panteghini C., Valletta L., Garavaglia B., Cowley M.J., Gayevskiy V.,
RA   Roscioli T., Silberstein J.M., Hoffmann C., Raas-Rothschild A.,
RA   Tiranti V., Anikster Y., Christodoulou J., Kastaniotis A.J.,
RA   Ben-Zeev B., Hayflick S.J.;
RT   "MECR mutations cause childhood-onset dystonia and optic atrophy, a
RT   mitochondrial fatty acid synthesis disorder.";
RL   Am. J. Hum. Genet. 99:1229-1244(2016).
CC   -!- FUNCTION: Catalyzes the NADPH-dependent reduction of trans-2-enoyl
CC       thioesters in mitochondrial fatty acid synthesis (fatty acid
CC       synthesis type II). Fatty acid chain elongation in mitochondria
CC       uses acyl carrier protein (ACP) as an acyl group carrier, but the
CC       enzyme accepts both ACP and CoA thioesters as substrates in vitro.
CC       Has a preference for short and medium chain substrates, including
CC       trans-2-hexenoyl-CoA (C6), trans-2-decenoyl-CoA (C10), and trans-
CC       2-hexadecenoyl-CoA (C16). {ECO:0000269|PubMed:18479707,
CC       ECO:0000269|PubMed:27817865}.
CC   -!- CATALYTIC ACTIVITY: An acyl-[acyl-carrier protein] + NADP(+) = a
CC       trans-2,3-dehydroacyl-[acyl-carrier protein] + NADPH.
CC       {ECO:0000305|PubMed:12654921, ECO:0000305|PubMed:18479707}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=37 uM for trans-2-hexenoyl-CoA {ECO:0000269|PubMed:12654921,
CC         ECO:0000269|PubMed:18479707};
CC         KM=7.1 uM for trans-2-decenoyl-CoA {ECO:0000269|PubMed:12654921,
CC         ECO:0000269|PubMed:18479707};
CC         KM=3.6 uM for trans-dodec-2-enoyl-CoA
CC         {ECO:0000269|PubMed:12654921, ECO:0000269|PubMed:18479707};
CC         KM=10.4 uM for trans-dec-2-enoyl-CoA
CC         {ECO:0000269|PubMed:12654921, ECO:0000269|PubMed:18479707};
CC         KM=10.2 uM for trans-oct-2-enoyl-CoA
CC         {ECO:0000269|PubMed:12654921, ECO:0000269|PubMed:18479707};
CC         KM=4.3 uM for trans-tetradec-2-enoyl-CoA
CC         {ECO:0000269|PubMed:12654921, ECO:0000269|PubMed:18479707};
CC         KM=6.6 uM for trans-hexadec-2-enoyl-CoA
CC         {ECO:0000269|PubMed:12654921, ECO:0000269|PubMed:18479707};
CC         KM=63.5 uM for trans-hex-2-enoyl-CoA
CC         {ECO:0000269|PubMed:12654921, ECO:0000269|PubMed:18479707};
CC   -!- SUBUNIT: Homodimer (PubMed:12654921, PubMed:18479707). Isoform 2
CC       interacts with PPARA in the nucleus and increases its activity (By
CC       similarity). {ECO:0000250|UniProtKB:Q9Z311,
CC       ECO:0000269|PubMed:12654921, ECO:0000269|PubMed:18479707}.
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Mitochondrion
CC       {ECO:0000269|PubMed:12654921}.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Cytoplasm
CC       {ECO:0000269|PubMed:25031892}. Nucleus
CC       {ECO:0000269|PubMed:25031892}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9BV79-1; Sequence=Displayed;
CC       Name=2; Synonyms=cMECR;
CC         IsoId=Q9BV79-2; Sequence=VSP_041131;
CC   -!- TISSUE SPECIFICITY: Highly expressed in skeletal and heart muscle.
CC       Expressed at lower level in placenta, liver, kidney and pancreas.
CC       Weakly or not expressed in lung. {ECO:0000269|PubMed:12654921}.
CC   -!- DISEASE: Dystonia, childhood-onset, with optic atrophy and basal
CC       ganglia abnormalities (DYTOABG) [MIM:617282]: An autosomal
CC       recessive neurologic disorder characterized by childhood-onset
CC       dystonia, basal ganglia degeneration and optic atrophy with
CC       decreased visual acuity. Dystonia is defined by the presence of
CC       sustained involuntary muscle contraction, often leading to
CC       abnormal postures. DYTOABG severity is variable, and some patients
CC       lose independent ambulation. {ECO:0000269|PubMed:27817865}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the zinc-containing alcohol dehydrogenase
CC       family. Quinone oxidoreductase subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAD34058.1; Type=Frameshift; Positions=14, 19; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF151821; AAD34058.1; ALT_FRAME; mRNA.
DR   EMBL; AK095099; BAG52984.1; -; mRNA.
DR   EMBL; CR456703; CAG32984.1; -; mRNA.
DR   EMBL; AL590729; CAI14329.1; -; Genomic_DNA.
DR   EMBL; AL590729; CAI14330.1; -; Genomic_DNA.
DR   EMBL; CH471059; EAX07655.1; -; Genomic_DNA.
DR   EMBL; BC001419; AAH01419.1; -; mRNA.
DR   CCDS; CCDS30659.1; -. [Q9BV79-1]
DR   CCDS; CCDS30660.1; -. [Q9BV79-2]
DR   RefSeq; NP_001019903.2; NM_001024732.2.
DR   RefSeq; NP_057095.3; NM_016011.3.
DR   RefSeq; XP_005245944.1; XM_005245887.2. [Q9BV79-2]
DR   RefSeq; XP_016856902.1; XM_017001413.1. [Q9BV79-2]
DR   RefSeq; XP_016856903.1; XM_017001414.1. [Q9BV79-2]
DR   RefSeq; XP_016856904.1; XM_017001415.1. [Q9BV79-2]
DR   UniGene; Hs.183646; -.
DR   PDB; 1ZSY; X-ray; 1.75 A; A=40-373.
DR   PDB; 2VCY; X-ray; 2.41 A; A/B=31-373.
DR   PDBsum; 1ZSY; -.
DR   PDBsum; 2VCY; -.
DR   ProteinModelPortal; Q9BV79; -.
DR   SMR; Q9BV79; -.
DR   BioGrid; 119291; 14.
DR   IntAct; Q9BV79; 2.
DR   STRING; 9606.ENSP00000263702; -.
DR   SwissLipids; SLP:000001054; -.
DR   iPTMnet; Q9BV79; -.
DR   PhosphoSitePlus; Q9BV79; -.
DR   DMDM; 334302832; -.
DR   EPD; Q9BV79; -.
DR   MaxQB; Q9BV79; -.
DR   PaxDb; Q9BV79; -.
DR   PeptideAtlas; Q9BV79; -.
DR   PRIDE; Q9BV79; -.
DR   DNASU; 51102; -.
DR   Ensembl; ENST00000263702; ENSP00000263702; ENSG00000116353. [Q9BV79-1]
DR   Ensembl; ENST00000373791; ENSP00000362896; ENSG00000116353. [Q9BV79-2]
DR   GeneID; 51102; -.
DR   KEGG; hsa:51102; -.
DR   UCSC; uc001brp.3; human. [Q9BV79-1]
DR   CTD; 51102; -.
DR   GeneCards; MECR; -.
DR   HGNC; HGNC:19691; MECR.
DR   HPA; HPA022018; -.
DR   HPA; HPA022030; -.
DR   HPA; HPA028740; -.
DR   MIM; 608205; gene.
DR   MIM; 617282; phenotype.
DR   neXtProt; NX_Q9BV79; -.
DR   OpenTargets; ENSG00000116353; -.
DR   PharmGKB; PA142671471; -.
DR   eggNOG; KOG0025; Eukaryota.
DR   eggNOG; COG0604; LUCA.
DR   GeneTree; ENSGT00870000136524; -.
DR   HOVERGEN; HBG052446; -.
DR   InParanoid; Q9BV79; -.
DR   KO; K07512; -.
DR   OMA; HQLCRAW; -.
DR   OrthoDB; EOG091G0BAE; -.
DR   PhylomeDB; Q9BV79; -.
DR   TreeFam; TF312886; -.
DR   SABIO-RK; Q9BV79; -.
DR   EvolutionaryTrace; Q9BV79; -.
DR   GeneWiki; MECR; -.
DR   GenomeRNAi; 51102; -.
DR   PRO; PR:Q9BV79; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000116353; -.
DR   CleanEx; HS_MECR; -.
DR   ExpressionAtlas; Q9BV79; baseline and differential.
DR   Genevisible; Q9BV79; HS.
DR   GO; GO:0005739; C:mitochondrion; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0019166; F:trans-2-enoyl-CoA reductase (NADPH) activity; IDA:UniProtKB.
DR   GO; GO:0006633; P:fatty acid biosynthetic process; IEA:UniProtKB-KW.
DR   GO; GO:0006631; P:fatty acid metabolic process; IDA:UniProtKB.
DR   InterPro; IPR013149; ADH_C.
DR   InterPro; IPR013154; ADH_N.
DR   InterPro; IPR011032; GroES-like.
DR   InterPro; IPR016040; NAD(P)-bd_dom.
DR   InterPro; IPR020843; PKS_ER.
DR   Pfam; PF08240; ADH_N; 1.
DR   Pfam; PF00107; ADH_zinc_N; 1.
DR   SMART; SM00829; PKS_ER; 1.
DR   SUPFAM; SSF50129; SSF50129; 1.
DR   SUPFAM; SSF51735; SSF51735; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Complete proteome;
KW   Cytoplasm; Disease mutation; Dystonia; Fatty acid biosynthesis;
KW   Fatty acid metabolism; Lipid biosynthesis; Lipid metabolism;
KW   Mitochondrion; NADP; Nucleus; Oxidoreductase; Polymorphism;
KW   Reference proteome; Transit peptide.
FT   TRANSIT       1     53       Mitochondrion. {ECO:0000255}.
FT   CHAIN        54    373       Enoyl-[acyl-carrier-protein] reductase,
FT                                mitochondrial.
FT                                /FTId=PRO_0000000888.
FT   NP_BIND     193    196       NADP. {ECO:0000250|UniProtKB:Q8WZM3}.
FT   NP_BIND     216    218       NADP. {ECO:0000250|UniProtKB:Q8WZM3}.
FT   NP_BIND     285    288       NADP. {ECO:0000250|UniProtKB:Q8WZM3}.
FT   NP_BIND     310    312       NADP. {ECO:0000250|UniProtKB:Q8WZM3}.
FT   ACT_SITE     94     94       Proton donor.
FT                                {ECO:0000250|UniProtKB:Q8WZM3}.
FT   BINDING     167    167       NADP. {ECO:0000250|UniProtKB:Q8WZM3}.
FT   BINDING     368    368       NADP. {ECO:0000250|UniProtKB:Q8WZM3}.
FT   MOD_RES      61     61       N6-acetyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:Q9DCS3}.
FT   MOD_RES      61     61       N6-succinyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:Q9DCS3}.
FT   MOD_RES     252    252       N6-acetyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:Q9DCS3}.
FT   MOD_RES     252    252       N6-succinyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:Q9DCS3}.
FT   MOD_RES     267    267       N6-acetyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:Q9DCS3}.
FT   MOD_RES     267    267       N6-succinyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:Q9DCS3}.
FT   MOD_RES     316    316       N6-succinyllysine.
FT                                {ECO:0000250|UniProtKB:Q9DCS3}.
FT   VAR_SEQ       1     76       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_041131.
FT   VARIANT      96     96       F -> L (in dbSNP:rs1128400).
FT                                {ECO:0000269|PubMed:10810093,
FT                                ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|Ref.3, ECO:0000269|Ref.5}.
FT                                /FTId=VAR_027935.
FT   VARIANT     227    227       R -> K (in dbSNP:rs11544658).
FT                                /FTId=VAR_055486.
FT   VARIANT     232    232       G -> E (in DYTOABG; probably decreased
FT                                protein abundance).
FT                                {ECO:0000269|PubMed:27817865}.
FT                                /FTId=VAR_077997.
FT   VARIANT     258    258       R -> L (in dbSNP:rs34835902).
FT                                /FTId=VAR_055487.
FT   VARIANT     258    258       R -> W (in DYTOABG).
FT                                {ECO:0000269|PubMed:27817865}.
FT                                /FTId=VAR_077998.
FT   VARIANT     285    373       Missing (in DYTOABG; probably decreased
FT                                protein abundance).
FT                                {ECO:0000269|PubMed:27817865}.
FT                                /FTId=VAR_077999.
FT   VARIANT     285    285       Y -> C (in DYTOABG).
FT                                {ECO:0000269|PubMed:27817865}.
FT                                /FTId=VAR_078000.
FT   MUTAGEN      85     85       S->A: Reduces catalytic activity by 68%.
FT                                {ECO:0000269|PubMed:18479707}.
FT   MUTAGEN      94     94       Y->F: Reduces catalytic activity by 95%.
FT                                Strongly reduces affinity for trans-oct-
FT                                2-enoyl-CoA.
FT                                {ECO:0000269|PubMed:18479707}.
FT   MUTAGEN     129    129       I->M: Strongly increases activity with
FT                                trans-oct-2-enoyl-CoA. No effect on
FT                                activity with trans-tetradec-2-enoyl-CoA.
FT                                Decreases activity with trans-hexadec-2-
FT                                enoyl-CoA by 20%.
FT                                {ECO:0000269|PubMed:18479707}.
FT   MUTAGEN     165    165       G->S: Strongly increases activity with
FT                                trans-oct-2-enoyl-CoA. Decreases activity
FT                                with trans-tetradec-2-enoyl-CoA by 73%.
FT                                Decreases activity with trans-hexadec-2-
FT                                enoyl-CoA by 80%.
FT                                {ECO:0000269|PubMed:18479707}.
FT   MUTAGEN     170    170       T->A: Reduces catalytic activity by 69%.
FT                                {ECO:0000269|PubMed:18479707}.
FT   MUTAGEN     311    311       W->A: Reduces catalytic activity by 98%.
FT                                Strongly reduces affinity for trans-oct-
FT                                2-enoyl-CoA.
FT                                {ECO:0000269|PubMed:18479707}.
FT   MUTAGEN     311    311       W->L: Reduces catalytic activity by 87%.
FT                                Strongly reduces affinity for trans-oct-
FT                                2-enoyl-CoA.
FT                                {ECO:0000269|PubMed:18479707}.
FT   MUTAGEN     324    324       F->Y: Strongly increases activity with
FT                                trans-oct-2-enoyl-CoA. Decreases activity
FT                                with trans-tetradec-2-enoyl-CoA by 25%.
FT                                Decreases activity with trans-hexadec-2-
FT                                enoyl-CoA by 68%.
FT                                {ECO:0000269|PubMed:18479707}.
FT   CONFLICT     45     46       AL -> GV (in Ref. 1; AAD34058).
FT                                {ECO:0000305}.
FT   CONFLICT    373    373       M -> I (in Ref. 2; CAG32984).
FT                                {ECO:0000305}.
FT   STRAND       43     52       {ECO:0000244|PDB:1ZSY}.
FT   HELIX        54     57       {ECO:0000244|PDB:1ZSY}.
FT   STRAND       58     63       {ECO:0000244|PDB:1ZSY}.
FT   STRAND       72     81       {ECO:0000244|PDB:1ZSY}.
FT   HELIX        84     91       {ECO:0000244|PDB:1ZSY}.
FT   STRAND      100    103       {ECO:0000244|PDB:1ZSY}.
FT   STRAND      109    115       {ECO:0000244|PDB:1ZSY}.
FT   STRAND      127    133       {ECO:0000244|PDB:1ZSY}.
FT   STRAND      138    145       {ECO:0000244|PDB:1ZSY}.
FT   HELIX       146    148       {ECO:0000244|PDB:1ZSY}.
FT   STRAND      149    152       {ECO:0000244|PDB:1ZSY}.
FT   STRAND      154    156       {ECO:0000244|PDB:1ZSY}.
FT   HELIX       158    163       {ECO:0000244|PDB:1ZSY}.
FT   HELIX       167    177       {ECO:0000244|PDB:1ZSY}.
FT   STRAND      186    191       {ECO:0000244|PDB:1ZSY}.
FT   HELIX       195    207       {ECO:0000244|PDB:1ZSY}.
FT   STRAND      210    215       {ECO:0000244|PDB:1ZSY}.
FT   HELIX       221    230       {ECO:0000244|PDB:1ZSY}.
FT   STRAND      234    238       {ECO:0000244|PDB:1ZSY}.
FT   HELIX       239    243       {ECO:0000244|PDB:1ZSY}.
FT   HELIX       245    249       {ECO:0000244|PDB:1ZSY}.
FT   STRAND      252    254       {ECO:0000244|PDB:1ZSY}.
FT   STRAND      258    264       {ECO:0000244|PDB:1ZSY}.
FT   HELIX       266    273       {ECO:0000244|PDB:1ZSY}.
FT   STRAND      281    284       {ECO:0000244|PDB:1ZSY}.
FT   STRAND      293    295       {ECO:0000244|PDB:2VCY}.
FT   HELIX       297    302       {ECO:0000244|PDB:1ZSY}.
FT   STRAND      306    309       {ECO:0000244|PDB:1ZSY}.
FT   HELIX       312    318       {ECO:0000244|PDB:1ZSY}.
FT   HELIX       321    336       {ECO:0000244|PDB:1ZSY}.
FT   STRAND      345    349       {ECO:0000244|PDB:1ZSY}.
FT   HELIX       350    352       {ECO:0000244|PDB:1ZSY}.
FT   HELIX       353    360       {ECO:0000244|PDB:1ZSY}.
FT   STRAND      362    364       {ECO:0000244|PDB:1ZSY}.
FT   STRAND      366    372       {ECO:0000244|PDB:1ZSY}.
SQ   SEQUENCE   373 AA;  40462 MW;  DB13F6B0ED54A823 CRC64;
     MWVCSTLWRV RTPARQWRGL LPASGCHGPA ASSYSASAEP ARVRALVYGH HGDPAKVVEL
     KNLELAAVRG SDVRVKMLAA PINPSDINMI QGNYGFLPEL PAVGGNEGVA QVVAVGSNVT
     GLKPGDWVIP ANAGLGTWRT EAVFSEEALI QVPSDIPLQS AATLGVNPCT AYRMLMDFEQ
     LQPGDSVIQN ASNSGVGQAV IQIAAALGLR TINVVRDRPD IQKLSDRLKS LGAEHVITEE
     ELRRPEMKNF FKDMPQPRLA LNCVGGKSST ELLRQLARGG TMVTYGGMAK QPVVASVSLL
     IFKDLKLRGF WLSQWKKDHS PDQFKELILT LCDLIRRGQL TAPACSQVPL QDYQSALEAS
     MKPFISSKQI LTM
//
